HomeCompareVIRI vs EPRT

VIRI vs EPRT: Dividend Comparison 2026

VIRI yields 1290.32% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIRI wins by $2.3960825995340865e+24M in total portfolio value
10 years
VIRI
VIRI
● Live price
1290.32%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.3960825995340865e+24M
Annual income
$2,395,725,921,261,555,500,000,000,000,000.00
Full VIRI calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — VIRI vs EPRT

📍 VIRI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVIRIEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VIRI + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VIRI pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VIRI
Annual income on $10K today (after 15% tax)
$109,677.42/yr
After 10yr DRIP, annual income (after tax)
$2,036,367,033,072,322,200,000,000,000,000.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, VIRI beats the other by $2,036,367,033,072,322,200,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VIRI + EPRT for your $10,000?

VIRI: 50%EPRT: 50%
100% EPRT50/50100% VIRI
Portfolio after 10yr
$1.1980412997670432e+24M
Annual income
$1,197,862,960,630,777,700,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

VIRI
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-882.0
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VIRI buys
0
EPRT buys
0
No recent congressional trades found for VIRI or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVIRIEPRT
Forward yield1290.32%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%29%
Portfolio after 10y$2.3960825995340865e+24M$64.3K
Annual income after 10y$2,395,725,921,261,555,500,000,000,000,000.00$13,170.85
Total dividends collected$2.3960592593715676e+24M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: VIRI vs EPRT ($10,000, DRIP)

YearVIRI PortfolioVIRI Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$268,765$258,064.52$11,212$512.01+$257.6KVIRI
2$13,251,799$12,964,221.46$12,689$692.09+$13.24MVIRI
3$1,208,980,447$1,194,801,021.45$14,521$944.30+$1208.97MVIRI
4$205,038,263,945$203,744,654,866.63$16,841$1,302.88+$205038.25MVIRI
5$64,806,832,428,888$64,587,441,486,467.30$19,841$1,821.64+$64806832.41MVIRI
6$38,226,866,599,812,776$38,157,523,289,113,870.00$23,818$2,587.47+$38226866599.79MVIRI
7$42,111,076,145,403,994,000$42,070,173,398,142,190,000.00$29,230$3,744.65+$42111076145403.96MVIRI
8$86,671,038,474,809,380,000,000$86,625,979,623,333,790,000,000.00$36,816$5,540.38+$86671038474809392.00MVIRI
9$333,344,179,935,764,700,000,000,000$333,251,441,924,596,600,000,000,000.00$47,806$8,413.17+$333344179935764676608.00MVIRI
10$2,396,082,599,534,086,500,000,000,000,000$2,395,725,921,261,555,500,000,000,000,000.00$64,324$13,170.85+$2.3960825995340865e+24MVIRI

VIRI vs EPRT: Complete Analysis 2026

VIRIStock

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

Full VIRI Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this VIRI vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VIRI vs SCHDVIRI vs JEPIVIRI vs OVIRI vs KOVIRI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.